Gene therapy for inherited muscle diseases: Where genetics meets rehabilitation medicine

American Journal of Physical Medicine and Rehabilitation

Volumn 93, Issue 11, 2014, Pages S97-S107

  Braun, Robynne ^a   Wang, Zejing ^b   Mack, David L ^a   Childers, Martin K ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

Author keywords

Canine; Gene therapy; Muscle disease; Myopathy; Rehabilitation

Indexed keywords

ANIMAL; COHORT ANALYSIS; DISEASE MODEL; DOG; FORECASTING; GENE THERAPY; GENE VECTOR; HUMAN; MORTALITY; MULTIMODALITY CANCER THERAPY; MUSCULAR DISEASES; MUSCULAR DYSTROPHY, DUCHENNE; MYOPATHIES, STRUCTURAL, CONGENITAL; PROCEDURES; PROGNOSIS; REGENERATIVE MEDICINE; REHABILITATION MEDICINE; SURVIVAL; TREATMENT OUTCOME; TRENDS;

ANIMALS; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DOGS; FORECASTING; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MUSCULAR DISEASES; MUSCULAR DYSTROPHY, DUCHENNE; MYOPATHIES, STRUCTURAL, CONGENITAL; PHYSICAL AND REHABILITATION MEDICINE; PROGNOSIS; REGENERATIVE MEDICINE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84914703815     PISSN: 08949115     EISSN: 15377385     Source Type: Journal    
DOI: 10.1097/PHM.0000000000000138     Document Type: Article

References (83)

1. Kastelein JJ, Ross CJ, Hayden MR: From mutation identification to therapy: Discovery and origins of the first approved gene therapy in the Western world. Human Gene Ther 2013;24:472-8
2. Nayerossadat N, Maedeh T, Ali PA: Viral and nonviral delivery systems for gene delivery. Adv Biomed Res 2012;1:27
3. Ginn SL, Alexander IE, Edelstein ML, et al: Gene therapy clinical trials worldwide to 2012Van update. J Gene Med 2013;15:65-77
4. Byrne BJ: Pathway for approval of a gene therapy orphan product: Treading new ground. Mol Ther 2013;21:1465-6
5. Hacein-Bey-Abina S, Hauer J, Lim A, et al: Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010;363:355-64
6. Simonelli F, Maguire AM, Testa F, et al: Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2010;18:643-50
7. Maguire AM, High KA, Auricchio A, et al: Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: A phase 1 dose-escalation trial. Lancet 2009;374:1597-605
8. Chung DC, Lee V, Maguire AM: Recent advances in ocular gene therapy. Curr Opin Ophthalmol 2009;20:377-81
9. Wilson JM: Lessons learned fromthe gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab 2009;96:151-7
10. Asokan A, Schaffer DV, Samulski RJ: The AAV vector toolkit: Poised at the clinical crossroads. Mol Ther 2012;20:699-708
11. Choi VW, McCarty DM, Samulski RJ: AAV hybrid serotypes: Improved vectors for gene delivery. Curr Gene Ther 2005;5:299-310
12. Wang Z, Tapscott SJ, Storb R: Local gene delivery and methods to control immune responses in muscles of normal and dystrophic dogs. Methods Mol Biol 2011;709:265-75
13. Mendell JR, Rodino-Klapac LR, Rosales XQ, et al: Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol 2010;68:629-38
14. Mendell JR, Rodino-Klapac LR, Rosales-Quintero X, et al: Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol 2009;66:290-7
15. Mendell JR, Campbell K, Rodino-Klapac L, et al: Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 2010;363:1429-37
16. Wang Z, Kuhr CS, Allen JM, et al: Sustained AAVmediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther 2007;15:1160-6
17. Wang Z, Storb R, Halbert CL, et al: Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: A preclinical model for human therapies. Mol Ther 2012;20:1501-7
18. Jarmin S, Kymalainen H, Popplewell L, et al: New developments in the use of gene therapy to treat Duchenne muscular dystrophy. Expert Opin Biol Ther 2013
19. Fairclough RJ, Wood MJ, Davies KE, et al: Therapy for Duchenne muscular dystrophy: Renewed optimism from genetic approaches. Nat Rev Genet 2013;14:373-8
20. Hoffman EP, Bronson A, Levin AA, et al: Restoring dystrophin expression in Duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through. Am J Pathol 2011;179:12-22
21. Nelson SF, Crosbie RH, Miceli MC, et al: Emerging genetic therapies to treat Duchenne muscular dystrophy. Curr Opin Neurol 2009;22:532-8
22. Kinali M, Arechavala-Gomeza V, Feng L, et al: Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: A single-blind, placebo-controlled, doseescalation, proof-of-concept study. Lancet Neurol 2009;8:918-28
23. Van Deutekom JC, Janson AA, Ginjaar IB, et al: Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007;357:2677-86
24. Goemans NM, Tulinius M, Van Den Akker JT, et al: Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011;364:1513-22
25. Cirak S, Arechavala-Gomeza V, Guglieri M, et al: Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study. Lancet 2011;378:595-605
26. McDonald CM, Henricson EK, Han JJ, et al: The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve 2010;41:500-10
27. Barton-Davis ER, Cordier L, Shoturma DI, et al: Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999;104:375-81
28. Welch EM, Barton ER, Zhuo J, et al: PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007;447:87-91
29. Finkel RS, Flanigan KM, Wong B, et al: Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PLoS One 2013;8:e81302
30. Finkel RS: Read-through strategies for suppression of nonsense mutations in Duchenne/Becker muscular dystrophy: Aminoglycosides and ataluren (PTC124). J Child Neurol 2010;25:1158-64
31. Sonnemann KJ, Heun-Johnson H, Turner AJ, et al: Functional substitution by TAT-utrophin in dystrophindeficient mice. PLoS Med 2009;6:e1000083
32. Tinsley JM, Fairclough RJ, Storer R, et al: Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PLoS One 2011;6:e19189
33. Nguyen HH, Jayasinha V, Xia B, et al: Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice. Proc Natl Acad Sci USA 2002;99:5616-21
34. Cosford KL, Taylor SM, Thompson L, et al: A possible new inherited myopathy in a young Labrador retriever. Can Vet J 2008;49:393-7
35. Frase AR. The miracle of Nibs. 2009. http://www.joshuafrase.org/uploads/JFF-The story of Nibs.pdf
36. Heckmatt JZ, Sewry CA, Hodes D, et al: Congenital centronuclear (myotubular) myopathy. A clinical, pathological and genetic study in eight children. Brain 1985;108(pt 4):941-64
37. Jungbluth H, Wallgren-Pettersson C, Laporte J: Centronuclear (myotubular) myopathy. Orphanet J Rare Dis 2008;3:26
38. Laporte J, Hu LJ, Kretz C, et al: A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. Nat Genet 1996;13:175-82
39. Laporte J, Blondeau F, Buj-Bello A, et al: Characterization of the myotubularin dual specificity phosphatase gene family from yeast to human. Hum Mol Genet 1998;7:1703-12
40. Robinson FL, Dixon JE: Myotubularin phosphatases: Policing 3-phosphoinositides. Trends Cell Biol 2006;16:403-12
41. Buj-Bello A, Laugel V, Messaddeq N, et al: The lipid phosphatase myotubularin is essential for skeletal muscle maintenance but not for myogenesis in mice. Proc Natl Acad Sci USA 2002;99:15060-5
42. Dowling JJ, Vreede AP, Low SE, et al: Loss of myotubularin function results in T-tubule disorganization in zebrafish and human myotubular myopathy. PLoS Genet 2009;5:e1000372
43. Beggs AH, Bohm J, Snead E, et al: MTM1 mutation associated with X-linked myotubular myopathy in Labrador retrievers. Proc Natl Acad Sci USA 2010;107:14697-702
44. Buj-Bello A, Fougerousse F, Schwab Y, et al: AAVmediated intramuscular delivery of myotubularin corrects the myotubular myopathy phenotype in targeted murine muscle and suggests a function in plasma membrane homeostasis. Hum Mol Genet 2008;17:2132-43
45. Grange RW: Muscle function in a canine model of x-linked myotubular myopathy. Muscle Nerve 2012
46. Goddard MA, Mitchell EL, Smith BK, et al: Establishing clinical end points of respiratory function in large animals for clinical translation. Phys Med Rehabil Clin North Am 2012;23:75-94, xi
47. Butler D: French move past Genethon to genetherapy research. Nature 1993;361:671
48. Childers MK, Joubert R, Poulard K, et al: Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy. Sci Transl Med 2014;6:220ra210
49. McPherron AC, Lawler AM, Lee SJ: Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997;387:83-90
50. Beggs ML, Nagarajan R, Taylor-Jones JM, et al: Alterations in the TGFbeta signaling pathway in myogenic progenitors with age. Aging Cell 2004;3:353-61
51. Musaro A, McCullagh K, Paul A, et al: Localized IGF-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 2001;27:195-200
52. Scicchitano BM, Rizzuto E, Musaro A: Counteracting muscle wasting in aging and neuromuscular diseases: The critical role of IGF-1. Aging (Albany NY) 2009;1:451-7
53. Gomes AR, Soares AG, Peviani S, et al: The effect of 30 minutes of passive stretch of the rat soleus muscle on the myogenic differentiation, myostatin, and atrogin-1 gene expressions. Arch Phys Med Rehabil 2006;87:241-6
54. Le Brasseur NK, Schelhorn TM, Bernardo BL, et al: Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice. J Gerontol A Biol Sci Med Sci 2009;64:940-8
55. Ambrosio F, Tarabishy A, Kadi F, et al: Biological basis of exercise-based treatments for musculoskeletal conditions. PM R 2011;3:S59-63
56. Kjaer M: Role of extracellular matrix in adaptation of tendon and skeletal muscle to mechanical loading. Physiol Rev 2004;84:649-98
57. Goldspink G: Gene expression in muscle in response to exercise. J Muscle Res Cell Motil 2003;24:121-6
58. Khan KM, Scott A: Mechanotherapy: How physical therapists' prescription of exercise promotes tissue repair. Br J Sports Med 2009;43:247-52
59. Olesen JL, Heinemeier KM, Haddad F, et al: Expression of insulin-like growth factor I, insulin-like growth factor binding proteins, and collagen mRNA in mechanically loaded plantaris tendon. J Appl Physiol (1985) 2006;101:183-8
60. Heinemeier KM, Olesen JL, Schjerling P, et al: Short-term strength training and the expression of myostatin and IGF-I isoforms in rat muscle and tendon: Differential effects of specific contraction types. J Appl Physiol (1985) 2007;102:573-81
61. Jarvinen TA, Jarvinen TL, Kaariainen M, et al: Muscle injuries: Optimising recovery. Best Pract Res Clin Rheumatol 2007;21:317-31
62. Bryer SC, Koh TJ. Mechanical strain increases gene transfer to skeletal muscle cells. J Biomech 2007;40:1995-2001
63. Bartlett JS, Wilcher R, Samulski RJ: Infectious entry pathway of adeno-Associated virus and adenoassociated virus vectors. J Virol 2000;74:2777-85
64. Haastert K, Ying Z, Grothe C, et al: The effects of FGF-2 gene therapy combined with voluntary exercise on axonal regeneration across peripheral nerve gaps. Neurosci Lett 2008;443:179-83
65. Legerlotz K, Smith HK: Role of MyoD in denervated, disused, and exercised muscle. Muscle & nerve 2008;38:1087-1100
66. Ustanina S, Carvajal J, Rigby P, et al: The myogenic factor Myf5 supports efficient skeletal muscle regeneration by enabling transient myoblast amplification. Stem Cells 2007;25:2006-16
67. Gayraud-Morel B, Chretien F, Flamant P, et al: A role for the myogenic determination gene Myf5 in adult regenerative myogenesis. Dev Biol 2007;312:13-28
68. Anderson JE, Vargas C: Correlated NOS-Imu and myf5 expression by satellite cells in mdx mouse muscle regeneration during NOS manipulation and deflazacort treatment. Neuromuscul Disord 2003;13:388-96
69. Goldspink G: Impairment of IGF-I gene splicing and MGF expression associated with muscle wasting. Int J Biochem Cell Biol 2006;38:481-9
70. Sambasivan R, Comai G, Le Roux I, et al: Embryonic founders of adult muscle stem cells are primed by the determination gene Mrf4. Dev Biol 2013;381:241-55
71. Becker C, Della Gaspera B, Guyot M, et al: Expression of MRF4 protein in adult and in regenerating muscles in Xenopus. Dev Dyn 2003;227:445-9
72. Pavlath GK, Dominov JA, Kegley KM, et al: Regeneration of transgenic skeletal muscles with altered timing of expression of the basic helix-loop-helix muscle regulatory factor MRF4. Am J Pathol 2003;162:1685-91
73. Zhu LN, Ren Y, Chen JQ, et al: Effects of myogenin on muscle fiber types and key metabolic enzymes in gene transfer mice and C2C12 myoblasts. Gene 2013;532:246-52
74. Naka A, Iida KT, Nakagawa Y, et al: TFE3 inhibits myoblast differentiation in C2C12 cells via downregulating gene expression of myogenin. Biochem Biophys Res Commun 2013;430:664-9
75. Aguiar AF, Vechetti-Junior IJ, Alves De Souza RW, et al: MyoD and IGF-I regulate muscle mass but not fibertype conversion during resistance training in rats. In J SportsMed 2013;34:293-301
76. Dobaczewski M, Chen W, Frangogiannis NG: Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J Mol Cell Cardiol 2011;51:600-6
77. Ramos-Mondragon R, Galindo CA, Avila G: Role of TGF-beta on cardiac structural and electrical remodeling. Vasc Health Risk Manag 2008;4:1289-1300
78. Tsuchida K: Activins, myostatin and related TGF-beta family members as novel therapeutic targets for endocrine, metabolic and immune disorders. Curr Drug Targets Immune Endocr Metabol Disord 2004;4:157-66
79. Barberi L, Dobrowolny G, Pelosi L, et al: Muscle involvement and IGF-1 signaling in genetic disorders: New therapeutic approaches. Endocr Dev 2009;14:29-37
80. Giovannini S, Marzetti E, Borst SE, et al: Modulation of GH/IGF-1 axis: Potential strategies to counteract sarcopenia in older adults. Mech Ageing Dev 2008;129:593-601
81. Philippou A, Maridaki M, Halapas A, et al: The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology. In Vivo 2007;21:45-54
82. Musaro A, Dobrowolny G, Rosenthal N: The neuroprotective effects of a locally acting IGF-1 isoform. Exp Gerontol 2007;42:76-80
83. Grounds MD: Reasons for the degeneration of ageing skeletal muscle: A central role for IGF-1 signalling. Biogerontology 2002;3:19-24